a great 4d in #Munich with @myesmo.bsky.social. Spoke on the importance of sex after cancer & chaired a session on Breast Cancer in Young Women. With @tanjaspanic.bsky.social from #Slovenia my pal Matteo Lambertini from #Italy, Prof Inez Vaz-Luis from #France, and Antigoni Kretsi from #Greece

Day1 #ESMObreast25 a session on survivorship, sex & side effects. Important insights on life after breast cancer - coping with long-term effects to addressing sexuality and issues that deeply affect women during & after treatment. @drdonsdizon.bsky.social @myesmo.bsky.social @oncoalert.bsky.social

Thank you @tanjaspanic.bsky.social for speaking about "Patient perspective – what do WE really need?" at #SGBCC2025. The BIG Patient Partnership ensures that patient voice is heard at the early stage of research development & at every stage of BIG clinical trials.

We had the opportunity to catch up with @tanjaspanic.bsky.social at #SGBCC2025, where she talked on tailoring therapies for early #breastcancer, and importance of survivorship and patient advocacy!

Visit VJOncology.com for exclusive interviews and more!

#bcsm

OncoAlert🚨Network with our partners at ESSO, ESGO, MASCC & SIOG invite you to the #OncoAlertColloquium

NEXT WEEK!!

FREE REGISTRATION HERE👉 buff.ly/3CChgre
February 3-9, 2025 💯% Virtual & Interactive
@erikahamilton9.bsky.social
@drsgraff.bsky.social
@drjnaidoo.bsky.social
@hoperugo.bsky.social

United in our goals - equity of access for all our patients #WorldCancerDay2025 @oncoalert.bsky.social

Dr. Bianchini describes the 🐘 in the room at #SABCS24.

❓Are PD-L1 and PD1 not created equal in breast?

🔑It is clear, neoadjuvant compared to adj immunotherapy should be given

⚠️ highlights ER low should be included in ICI trials

#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social

To build on the progress shared at #SABCS24 for triple-positive MBC ( #PATINA), when treatments stop working, is it the HER2 or HR component driving resistance? Need a biomarker! Patients want the most mileage from every treatment!

PS: Finally, +++ is being treated differently from HER2+/HR–.

Dr. Bianchini describes the 🐘 in the room at #SABCS24.

❓Are PD-L1 and PD1 not created equal in breast?

🔑It is clear, neoadjuvant compared to adj immunotherapy should be given

⚠️ highlights ER low should be included in ICI trials

#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social

#SABCS24 #bcsm #OncSky

We need to ask all patients on endocrine therapy for #breastcancer about vaginal dryness & sexual dysfunction. Here’s a useful stepwise approach to managing these issues from
@JenniShengMD. #MedSky

@oncoalert.bsky.social